Attention is paid to ‘Sleepy Sol’, a digital treatment solution for mental health such as sleep disorders and depression
Healthcare start-up Lysol announced on the 30th that it won the Innovation Award at the “Next Rise 2025” event held at COEX in Samseong-dong, Seoul from June 26-27.
“Nextrise” is the largest startup event in Korea that the Korea International Trade Association and the Korea Development Bank have co-hosted since 2019. This year, 1,100 startups from 28 countries and 250 domestic and foreign large and medium-sized companies and investment companies participated.
Lysol was named the winner of the Innovation Award in comprehensive recognition of technology accumulated in the field of specialized treatment devices, clinical performance, commercialization experience, and collaboration capabilities with large companies, as well as the performance of wellness products for general consumers.
Lysol participated in the exhibition booth and introduced technologies and products that reflected its specialized treatment device lineup and wellness lineup. Focusing on the “Sleepisol” series, a wearable device that combines microcurrent-based EEG tuning technology and AI-based bio-signal analysis algorithm, it introduced digital treatment solutions specialized in mental health care such as sleep disorders and depression, drawing attention from global companies and investment institutions.
Currently, Lysol’s “Sleepy Sol” series is sold in Korea, Japan, and the United States, and has also passed the U.S. Food and Drug Administration (FDA) safety standards after clinical trials at Seoul National University Bundang Hospital. In particular, Samsung Health SDK-based sleep management app “Sleepysol Bio” has surpassed 600,000 cumulative downloads, and commercialization results are also visible.
Lysol was recently selected as Daewoong Group’s open innovation program ‘Innovare 4th’, and will conduct digital therapy-based POC (concept verification) and marketing cooperation with major affiliates such as Daewoong Pharmaceutical, Hanol Biopharma, CG Bio, Daewoong Pet, and Daewoong Therapeutics.
“The Nextrise Innovation Award is an achievement of official recognition of technology and commercialization capabilities accumulated in the medical device and digital health sector,” said Kwon Sung-koo, co-chairman of Lysol. “We will lead the global digital therapy market based on practical clinical effects and market reactions through collaboration with various industrial partners including Daewoong Group.”
link